Prospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Sep 21, 2017; 23(35): 6482-6490
Published online Sep 21, 2017. doi: 10.3748/wjg.v23.i35.6482
Table 1 Patient characteristics, n = 48
Characterizationn (%)
Women,22 (45.8)
Median time between diagnosis and surgery, mo (IQR)36.0 (14.0-120.0)
Median time between surgery and endoscopic evaluation, mo (IQR)114.5 (60.8-199.0)
Median age at endoscopic evaluation, yr (IQR)46.5 (39.3-53.4)
Montreal classification
Age at diagnosis
A1, ≤ 16 yr6 (12.5)
A2, 17-40 yr33 (68.8)
A3, > 40 yr9 (18.8)
Location
L1: ileal30 (62.5)
L3: ileocolonic17 (35.4)
L4: upper gastrointestinal tract1 (2.1)
Behavior
B1: non-stricturing, non-penetrating1 (2.1)
B2: stricturing27 (56.2)
B3: penetrating20 (41.7)
Perianal disease14 (29.2)
Smoking
Never26 (54.2)
Current12 (25.0)
Past10 (20.8)
Concomitant treatment
Corticosteroids9 (18.8)
Immunomodulators (Azathioprine/6MP/ Methotrexate)26 (54.2)
Biologics (Infliximab, adalimumab)20 (41.7)
5-ASA17 (35.4)
Median fecal calprotectin, μg/g (IQR)134.0 (35.3-321.0)
Median, fecal lactoferrin, μg/g (IQR)6.2 (2.0-22.4)
Modified Rutgeerts score
i0, i1, i2a26 (54.2)
i2b, i3, i422 (45.8)
Subocclusive symptoms8 (16.7)
Harvey-Bradshaw index
Remission (HBI < 5)40 (83.3)
Mild disease (HBI 5-7)8 (16.7)
Need of redilation14 (29.2)
Surgery after dilation2 (1.4)
Median follow up, mo (IQR)34.0 (27.5-52.5)
Table 2 Characterization of the dilation procedure
Characterizationn (%)
Patients with stricture58 (32.6)
Stricture type
Anastomotic58 (100)
Dilated patients52 (29.2)
Causes for non-dilation
Length of stenosis2 (33.3)
Ulceration of mucosa3 (50.0)
Technical inability1 (16.7)
Successful dilated patients
Balloon size, n = 5248 (92.3)
15 mm13 (25.0)
16.5 mm3 (5.8)
18 mm36 (69.2)
Complications0 (0.0)
Table 3 Comparison between patients with and without endoscopic recurrence
Endoscopic recurrence,n = 22No endoscopic recurrence,n = 26P value
Sex, M:F11:1115:110.404
Median age, yr (IQR)47.0 (35.5-53.3)46.5 (39.8-54.8)0.472
Median hemoglobin, g/dL (IQR)13.8 (12.5-15.1)13.9 (13.1-15.0)0.715
Median albumin, g/L (IQR)42.4 (36.1-45.9)42.1 (39.8-44.6)0.886
Median C-reactive protein, mg/L (IQR)5.6 (1.6-8.2)2.4 (0.9-9.9)0.457
Median fecal calprotectin, μg/g (IQR)257.0 (161.0-565.0)53.9 (23.9-146.0)< 0.001
Median fecal lactoferrin, μg/g (IQR)9.1 (5.5-27.8)3.9 (1.5-21.9)0.042
Smoking, yes/no/past3/13/69/13/40.196
Subocclusive symptoms, yes/no2/206/200.183
HBI, remission/mild17/524/20.145
Concomitant treatment
Anti-TNF- α agents, yes/no12/1014/120.596
Immunomodulators, yes/no9/1311/150.578
Steroids, yes/no4/185/210.611